Capraru Annina, Jalowiec Katarzyna Aleksandra, Medri Cesare, Daskalakis Michael, Zeerleder Sacha Sergio, Mansouri Taleghani Behrouz
Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
Department of Biomedical Research, University of Bern, 3010 Bern, Switzerland.
J Clin Med. 2021 May 6;10(9):1990. doi: 10.3390/jcm10091990.
Since the late sixties, therapeutic or prophylactic platelet transfusion has been used to relieve hemorrhagic complications of patients with, e.g., thrombocytopenia, platelet dysfunction, and injuries, and is an essential part of the supportive care in high dose chemotherapy. Current and upcoming advances will significantly affect present standards. We focus on specific issues, including the comparison of buffy-coat (BPC) and apheresis platelet concentrates (APC); plasma additive solutions (PAS); further measures for improvement of platelet storage quality; pathogen inactivation; and cold storage of platelets. The objective of this article is to give insights from current practice to future development on platelet transfusion, focusing on these selected issues, which have a potentially major impact on forthcoming guidelines.
自20世纪60年代末以来，治疗性或预防性血小板输注已被用于缓解例如血小板减少症、血小板功能障碍和损伤患者的出血并发症，并且是高剂量化疗支持治疗的重要组成部分。当前和即将取得的进展将显著影响当前的标准。我们关注特定问题，包括 Buffy 层血小板（BPC）和单采血小板浓缩物（APC）的比较；血浆添加剂溶液（PAS）；改善血小板储存质量的进一步措施；病原体灭活；以及血小板的冷藏。本文的目的是就血小板输注从当前实践到未来发展提供见解，重点关注这些对即将出台的指南可能产生重大影响的选定问题。
